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From the Editor’s Desk
CENTRALISING THE 
BLAME GAME
An abiding feature of our health system is 
the “blame game” — a political shield for 
deflecting criticisms and disowning 
responsibilities in health care. The 
prominent health commentator John 
Menadue argues that:
. . . we must resolve this problem to ensure 
integrated care and the avoidance of cost 
and blame shifting. Both federal and state 
governments have a vested interest in the 
present system.
And a suggested solution? A single health 
funder and provider .. . the Australian 
Government!
But would this be an improvement? 
Probably not — especially if its prototype 
is the United Kingdom’s National Health 
Service.
Over the past two decades, the NHS has 
seen wave after wave of destabilising 
change. British doctors have had to confront 
an internal market system (in 1991); 
general practice fund-holding (1992); 
abolition of regional health authorities and 
the creation of nine health offices (1996); 
abolition of fund-holding (1996); a target 
plan for improving care and cutting waiting 
times (2000); the introduction of hospital 
league tables (2001); primary care trusts 
taking on the planning and commissioning 
of health care (2002); a hundred-odd health 
authorities replaced by 28 strategic health 
bodies (2002); the introduction of 
foundation trusts (2004); payment by 
health results (2005);  primary care trusts 
cut from 302 to 152 and strategic health 
authorities from 28 to 10 (2006); and the 
abolition of hospital league tables (2006).
This period also saw a culling and 
reconfiguration of hospital services, the 
introduction of Patient Choice — a program 
that requires a patient to have a choice of 
four or more providers when referred by a 
general practitioner — and muddled 
meddling with vocational training, through 
the disastrous Modernising Medical Careers 
and with the governance of the General 
Medical Council.
Given this record of continuous and 
chaotic change engineered by a central 
Department of Health, the blame game may 
well be the lesser of two evils.
Martin B Van Der Weyden
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Letters
Cost of hepatitis A vaccine: 
$70. Mounting your own 
antibody response to 
hepatitis A before your 
overseas holiday: priceless
Jake Shortt, Denis Spelman and 
Erica M Wood
TO THE EDITOR: Human normal immu-
noglobulin (NIG) has historically been used
to provide passive immunity against hepati-
tis A infection for susceptible travellers to
areas where the virus is endemic.1 The
introduction of effective hepatitis A vaccines
in recent years (which result in active, long-
term immunity to the virus) should have
largely replaced the use of NIG for travel
prophylaxis.2 However, the Australian Red
Cross Blood Service still receives requests to
supply NIG for travellers, even though the
intended recipients have no contraindica-
tions to vaccination.
Requests for use of NIG for this purpose
appear in many cases to be a consequence of
the “out-of-pocket” cost to the patient of the
hepatitis A vaccine, which is about $70–
$100 (depending on the formulation used
and the private dispensing fee charged). In
contrast, NIG is provided free of charge to
the recipient, but the community still incurs
substantial costs related to blood collection
and fractionation of plasma products. There
is also the concern of unnecessary exposure
of a healthy traveller to a pooled plasma
product, which, despite blood donor screen-
ing, dedicated viral inactivation steps, and
an excellent safety record in Australia, may
theoretically transmit infectious agents. In
addition, even if a small amount of NIG is
used for this purpose, the plasma source
would be better used for production of
greater amounts of other scarce plasma-
derived products (such as intravenous
immunoglobulin).
While NIG can effectively prevent hepati-
tis A infection from developing in suscepti-
ble contacts, immunity is short-lived and
likely to be inferior to the results of active
vaccination.1-3 Accordingly, NIG is only
indicated for at-risk people who have a
contraindication to vaccination, or in whom
there is insufficient time to mount an endo-
genous antibody response (active immunity
develops within 7–10 days of vaccination,3
and vaccination may also prevent hepatitis A
infection even when the vaccine has been
administered up to a week after exposure4).
Use of NIG is also appropriate where at-risk
contacts may be unable to mount a protec-
tive antibody response because they have a
congenital or acquired immune deficiency.
Although the extent of NIG use for
travellers appears to be limited, we wish
to highlight that, in the absence of con-
traindications to vaccination, it can no
longer be advocated as best practice, and
it is certainly not an appropriate cost-
saving measure.
Jake Shortt, Haematology Registrar, 
Transfusion Medical Services1
Denis Spelman, Head of Microbiology and 
Deputy Director2
Erica M Wood, Transfusion Medicine Specialist1
1 Australian Red Cross Blood Service, 
Melbourne, VIC.
2 Infectious Diseases Unit, The Alfred Hospital, 
Melbourne, VIC.
jshortt@ausdoctors.net
1 Koff RS. Hepatitis A. Lancet 1998; 351: 1643-
1649.
2 Webster G, Barnes E, Dusheiko G, Franklin I.
Protecting travellers from hepatitis A. BMJ
2001; 322: 1194-1195.
3 Ashur Y, Adler R, Rowe M, Shouval D. Compari-
son of immunogenicity of two hepatitis A vac-
cines — VAQTA and HAVRIX — in young
adults. Vaccine 1999; 17: 2290-2296.
4 Sagliocca L, Amoroso P, Stroffolini T, et al.
Efficacy of hepatitis A vaccine in prevention of
secondary hepatitis A infection: a randomised
trial. Lancet 1999; 353: 1136-1139. ❏
Intradermal rabies vaccine
Anthony Gherardin and Sonny Lau
TO THE EDITOR: Rabies vaccine is rec-
ommended for pre-exposure prophylaxis
in travellers over 1 year old who intend to
travel to predominantly developing coun-
tries where canine rabies is endemic. The
incidence of dog bites in such countries is
relatively high, being more common
among travellers than typhoid fever.1 Post-
exposure rabies treatment of pre-immu-
nised travellers is simpler, cheaper and
safer than treatment of those who have not
been immunised.
Rabies vaccines currently available in
Australia are given intramuscularly as three
doses of 1.0 mL on Days 0, 7, and 21–28,
but are relatively expensive at more than
$100 per dose. Some travellers will choose
not to be vaccinated because of this cost.
For at-risk travellers who might choose to
decline vaccination because of the cost, and
to facilitate use of pre-exposure vaccination
in poorer countries, the World Health
Organization approves the intradermal
route of vaccination, where 0.1 mL of vac-
cine is administered, also on Days 0, 7 and
21–28.2
However, the intradermal technique is
technically more difficult, may result in
lower antibody levels that decline more
quickly, and may be interfered with by
concurrent administration of chloroquine
or immunosuppressants. The Australian
immunisation handbook therefore recom-
mends that this technique be performed by
vaccinators experienced in the technique,
and that satisfactory antibody production is
confirmed after vaccination.3 Antibody lev-
els of at least 0.5 IU/mL are considered
protective, and the commercial enzyme
immunoassay, available under Medicare,
has been shown to correlate well with the
gold-standard virus neutralisation test.4
We have been using the intradermal
method for over 10 years for travellers
considered at high risk, but who decline
vaccine on cost alone; we use imported
human diploid cell vaccine of potency of at
least 2.5 IU/mL. As several travellers can be
vaccinated from the same vial, costs are
$30–$40 per dose, and vials can be stored
and reused within 7 days under aseptic
conditions. However, travellers must be
vaccinated 7–8 weeks before departure to
enable antibody testing and a booster vac-
cination if required.
Recent analysis of 1532 non-immuno-
suppressed travellers (aged between 9 and
77 years; 55% female) who received three
intradermal doses of 0.1 mL rabies vaccine
on Days 0, 7, and 21–28 in our Melbourne
clinic showed that only seven (0.46%)
failed to reach the protective antibody level
of 0.5 IU/mL on testing 2–4 weeks after the
third dose, with readings of 0.4 IU/mL (in
four), 0.3 IU/mL (in two) and 0.2 IU/mL
(in one). None had undetectable antibody
levels. All seven were advised to receive an
intramuscular booster dose of 1.0 mL.
These data support the contention that
the intradermal method is appropriate for
use in travellers who may otherwise decline
pre-exposure rabies vaccination, when the
vaccine is administered by vaccinators with
relevant experience.5
Recipients of intradermal rabies vaccine
who have satisfactory antibody levels may
be considered fully vaccinated in the post-
exposure situation and managed accordingly.
Anthony Gherardin, National Medical Advisor
Sonny Lau, Medical Director, Melbourne Clinic
The Travel Doctor (TMVC), Melbourne, VIC.
tony.gherardin@hfi.com.au58 MJA • Volume 187 Number 1 • 2 July 2007
LETTERS1 Steffen R, Connor BA. Vaccines in travel health:
from risk assessment to priorities. J Travel Med
2005; 12: 26-35.
2 World Health Organization. International travel and
health. Situation as on 1 January 2005. Geneva:
WHO, 2005.
3 National Health and Medical Research Council.
Australian immunisation handbook. 8th ed. Can-
berra: NHMRC, 2003.
4 Atanasiu P, Perrin P, Delagneau JF. Use of an
enzyme immunoassay with protein A for rabies
antigen and antibody determination. Dev Biol
Stand 1980; 46: 207-215.
5 Lau C, Sisson J. The effectiveness of intradermal
pre-exposure rabies vaccination in an Australian
travel medicine clinic. J Travel Med 2002; 9: 285-
288. ❏
Spontaneous intracranial 
hypotension: an easily 
treated headache
Mohamed Asif Chinnaratha, 
Ronald A Criddle and Paul J Graziotti
TO THE EDITOR: We report a patient with
spontaneous intracranial hypotension (SIH),
which is now an increasingly recognised
syndrome. Orthostatic headache with typi-
cal findings on magnetic resonance imaging
(MRI) are the keys to diagnosis. When
correctly diagnosed, SIH management is
easy and highly effective in most cases.
A 38-year-old woman presented to our
hospital after having daily headaches for 3
weeks. The acute onset of severe headache
occurred initially when she bent down and
tried to lift her 16-month-old child. The
headache began as a sharp pain over the right
side of her occiput and rapidly spread to her
frontal area. The headache was particularly
bad in the morning and while standing, and
was relieved by assuming a recumbent pos-
ture. Apart from nausea, she had no other
associated symptoms. General and systemic
examination findings were normal.
MRI of the brain showed diffuse dural
enhancement and smooth thickening of the
dura (Box, A) and a total spinal magnetic
resonance image showed fluid in the pos-
terior soft tissues at C1/C2 level (Box, B).
These findings confirmed the leak of cere-
brospinal fluid that accounted for the intra-
cranial hypotension and orthostatic
headache. Initial treatment with bed rest,
increased fluid intake and non-steroidal
anti-inflammatory drugs relieved her symp-
toms marginally. After a failed lumbar epi-
dural blood patch, 10 mL of autologous
blood was injected at the site of the cervical
level leak. The patient’s symptoms resolved,
and she was asymptomatic and had had no
recurrence at follow-up at 4 months.
Also known as Schaltenbrand syn-
drome, SIH is very rare, with a prevalence
of about 1 in 50 000 population, and a
female preponderance of 3:1.1 Patients
with connective tissue diseases2 or Chiari
malformation may be more susceptible to
SIH. Orthostatic headache is the cardinal
feature of this syndrome. Headache is
usually holocranial, although it might be
localised to the frontal or occipital
regions. Patients may have other symp-
toms such as diplopia and photophobia.
MRI with gadolinium is critical in diag-
nosing this syndrome. The condition of
most patients improves with conservative
therapy (bed rest, increased fluid intake
and caffeine). Epidural autologous blood
patch is effective in relieving low intracra-
nial pressure headaches.3 Surgical repair
of the leak is rarely used and should be
used only if medical therapy fails.4
Mohamed Asif Chinnaratha, Resident Medical 
Officer
Ronald A Criddle, Physician
Paul J Graziotti, Pain Management Physician
St John of God Hospital, Perth, WA.
drmohamedasif@hotmail.com
1 Blank SC, Shakir RA, Bindoff LA, Bradley N. Sponta-
neous intracranial hypotension: clinical and mag-
netic resonance imaging characteristics. Clin
Neurol Neurosurg 1997; 99: 199-204.
2 Schievink WI, Reimer R, Folger WN. Surgical treat-
ment of spontaneous intracranial hypotension
associated with a spinal arachnoid diverticulum.
Case report. J Neurosurg 1994; 80: 736-739.
3 Benzon HT, Nemickas R, Molloy RE, et al. Lumbar
and thoracic epidural blood injections to treat
spontaneous intracranial hypotension. Anesthesiol-
ogy 1996; 85: 920-922.
4 Schievink WI, Morreale VM, Atkinson JLD, et al.
Surgical treatment of spontaneous spinal cerebro-
spinal fluid leaks. J Neurosurg 1998; 88: 243-246. ❏
Australian children and 
adolescents with type 1 
diabetes have low vitamin D 
levels
Ristan M Greer, Meredith A Rogers, 
Francis G Bowling, Helen M Buntain, 
Mark Harris, Gary M Leong and 
Andrew M Cotterill
TO THE EDITOR: Recent studies provide
evidence that having a low serum vitamin
D level is a risk factor for autoimmune
disease, including type 1 diabetes mellitus
(T1DM).1,2 Available data come from
northern hemisphere countries where sun-
light exposure levels and the genetic back-
ground of the population are different from
those in Australia. We compared vitamin D
levels in stored serum from Brisbane chil-
dren and adolescents with T1DM who
attended the Mater Children’s Hospital
clinic with local historical control data
from a previous study.3
Levels of 25-hydroxyvitamin D (25-
OHD; the major circulating form of vitamin
D) were lower in those with T1DM than in
the control group, with no difference in
levels of 1,25-dihydroxyvitamin D (1,25-
[OH]2D; the biologically active form). Chil-
dren and adolescents with T1DM were
more than three times as likely to have
vitamin D deficiency4 as those in the con-
trol group. There was a trend towards
seasonal variation in 25-OHD levels, with
mean levels (95% CI) being 53.8 nmol/L
(47.0–60.6 nmol/L) in summer, 61.4 nmol/L
(54.9–67.9 nmol/L) in autumn, 56.4 nmol/L
(51.7–61.0 nmol/L)  in  win ter  and
64.7 nmol/L (58.8–70.6 nmol/L) in spring
Magnetic resonance images of the 
patient’s brain and cervical spine
A: Diffuse dural enhancement and smooth 
thickening of the pachymeninges.
B: Fluid in the posterior soft tissues at C1/C2 
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variation between T1DM and control
groups (P = 0.73). There was no difference
in the ages or proportions of males and
females in the two groups (Box). There
were no differences in vitamin D levels
between the sexes in either T1DM or con-
trol groups, nor any correlation with dura-
tion of diabetes.
These observations support previous
reports. One found low 25-OHD levels in
459 Swedish patients aged between 15 and
34 years who were newly diagnosed with
T1DM compared with age-matched and
place-matched controls.1 Another found
low 25-OHD levels in 88 newly diagnosed
children and adolescents.2 Understanding
the nature of low vitamin D levels in people
with diabetes is important because it
potentially clarifies the mechanisms of
autoimmune β-cell destruction, and may
lead to interventions for preventing or
delaying insulin dependence by using vita-
min D or its analogues. Vitamin D probably
acts by modifying the autoimmune
response, as 1,25-(OH)2D modulates den-
dritic cell function to promote tolerogenic
T cells. It may be relevant that we have
recently found low blood dendritic cell
counts in children and adolescents with
T1DM.5
Vitamin D levels in our Queensland sam-
ple of children and adolescents were lower
overall than those found in the subjects of
the Swedish study, (mean 25-OHD levels
[± SEM] were 96.7 ± 2.7 nmol/L for the
control group and 82.5 ± 1.3 nmol/L for
those with T1DM); this is unexpected
given Brisbane’s latitude (29°S) compared
with that of Sweden (about 55–65° N).
These differences might be explained by
differences in dietary intake, sun avoidance
behaviours promoted in Queensland, or
differences in the assays used, as the Swed-
ish group used the Nichols chemilumines-
cence assay (Nichols Institute, San Juan
Capistrano, Calif, USA) and we used the
DiaSorin radioimmunoassay (DiaSorin Inc,
Stillwater, Minn, USA). The observation in
the Swedish study that the deficit in 25-
OHD level did not resolve over time after
diagnosis concurs with our finding of low
levels in children and adolescents several
years after diagnosis.
While our pilot data cannot support
causal inference, and is limited by being
retrospective and our lack of information
about history of sunlight exposure, dietary
vitamin D intake, cultural factors such as
sun avoidance or veiling, skin tone, and
not having contemporaneous controls, it
strongly supports the case for prospective
clinical studies of vitamin D in T1DM.
Acknowledgements: We thank Dr Slavica Vucko-
vic of the Mater Medical Research Institute for
helpful discussions on the role of dendritic cells in
autoimmune disease.
Ristan M Greer, Lecturer, Paediatrics and Child 
Health1
Meredith A Rogers, Research Assistant, 
Paediatric Endocrinology and Diabetes2
Francis G Bowling, Professor of Medical 
Biochemistry and Director of Biochemical 
Diseases2
Helen M Buntain, Respiratory Physician3
Mark Harris, Paediatric Endocrinologist2
Gary M Leong, NHMRC Senior Research 
Officer, Institute for Molecular Bioscience,1 
and Paediatric Endocrinologist2
Andrew M Cotterill, Associate Professor, 
Paediatrics and Child Health,1 and Director, 
Paediatric Endocrinology and Diabetes3
1 University of Queensland, Brisbane, QLD.
2 Mater Children’s Hospital, Brisbane, QLD.
3 Royal Children’s Hospital, Brisbane, QLD.
r.greer@uq.edu.au
1 Littorin B, Blom P, Scholin A, et al. Lower levels of
plasma 25-hydroxyvitamin D among young adults
at diagnosis of autoimmmune type 1 diabetes
compared with control subjects: results from the
nationwide Diabetes Incidence Study in Sweden
(DISS). Diabetologia 2006; 49: 2847-2852.
2 Pozzilli P, Manfrini S, Crino A, et al. Low levels of
25-hydroxyvitamin D3 and 1,25-dihydroxyvitamin
D3 in patients with newly diagnosed type 1 diabe-
tes. Horm Metab Res 2005; 37: 680-683.
3 Greer RM, Buntain HM, Potter JM, et al. Abnor-
malities of the PTH-vitamin D axis and bone turn-
over markers in children, adolescents and adults
with cystic fibrosis: comparison with healthy con-
trols. Osteoporos Int 2003; 14: 404-411.
4 Munns C, Zacharin MR, Rodda CP, et al. Prevention
and treatment of infant and childhood vitamin D
deficiency in Australia and New Zealand: a consen-
sus statement. Med J Aust 2006; 185: 268-272. 
5 Vuckovic S, Withers G, Harris M, et al. Decreased
blood dendritic cell counts in type 1 diabetic
children. Clin Immunol 2007; Apr 24 [Epub ahead
of print]. ❏
Comparison of clinical characteristics and vitamin D levels in healthy children and adolescents and those with type 1 
diabetes mellitus
Variable Control group Type 1 diabetes mellitus group P
No. of children and adolescents 94 47
Age (range) 13.2 years (12.5–13.8 years) 13.6 years (12.6–14.6 years) 0.47*
No. of males/females 44/50 21/26 0.81†
Mean duration of diabetes (95% CI) — 4.7 years (3.9–5.5 years)
Sample collection period July 2000 – December 2001 June 2001 – July 2006
Mean 25-OHD level (95%CI)‡ 64.6 nmol/L (61.3–67.9 nmol/L) 54.7 nmol/L (50.3–58.9 nmol/L) 0.0005*
Mean 1,25-(OH)2D level (95% CI)
‡ 126.7 pmol/L (115.8–137.6 pmol/L)§ 127.6 pmol/L (114.8–140.4 pmol/L) 0.92*
Proportion 25-OHD-deficient 
( 50 nmol/L)
18% (17/94) 43% (20/47) 0.002†
(OR,¶ 3.4; 95% CI, 1.5–7.3)
Proportion with 1,25-(OH)2D level 
below reference range 
(40–150 pmol/L)
0 (0/84) 4% (2/47) 0.13** 
(OR,¶ 9.3; 95% CI, 0.4–197.6)
* t test. † χ2 test. ‡ DiaSorin radioimmunoassay double antibody assay (DiaSorin Inc, Stillwater, Minn, USA), performed by Queensland Health Pathology Services. 
§ 84 controls; insufficient serum for analysis in 10. ¶ Odds ratio for deficiency in type 1 diabetes mellitus. ** Fisher’s exact test.
25-OHD = 25-hydroxyvitamin D. 1,25-(OH)2D = 1,25-dihydroxyvitamin D. ◆60 MJA • Volume 187 Number 1 • 2 July 2007
LETTERSRevisiting the metabolic 
syndrome
Tomi-Pekka Tuomainen
TO THE EDITOR: I read with interest the
excellent review article on the metabolic syn-
drome by Chew et al in the 16 October 2006
issue of the Journal.1 In their article the
authors claim there is a lack of data about the
relationship between hyperinsulinaemia and
changes in free testosterone levels.
As part of the Kuopio Ischaemic Heart
Disease (KIHD) Risk Factor Study, an ongo-
ing prospective epidemiological study of
2682 middle-aged Finnish men investigating
risk factors for chronic disease, our research
group has shown an association between the
presence of metabolic syndrome at baseline
and a change in sex hormone levels at follow-
up after 11 years.2 In our study, men who met
the World Health Organization criteria for
metabolic syndrome both at baseline and at
11-year follow-up were at 2.6-fold increased
risk of developing hypogonadism (serum
total testosterone concentration < 11 nmol/L)
during the study period compared with men
who did not have metabolic syndrome. There
was also a non-significant trend for men with
metabolic syndrome to develop hypogonad-
ism as defined by calculated free testosterone
levels of < 225 pmol/L at 11-year follow-up.2
In the same cohort, we also reported a
reverse association — that is, hypogonadism
predicting metabolic syndrome.3,4 However,
as the question posed by Chew et al was
whether hyperinsulinaemia affects free testo-
sterone levels, I examined the KIHD data
further for evidence of such an association. I
found that subjects grouped in ascending
baseline fasting serum insulin quartiles had
baseline mean free testosterone levels of
316 pmol/L (SD, 72 pmol/L), 312 pmol/L
(SD, 77 pmol/L), 299 pmol/L (SD, 74 pmol/L)
and 271 pmol/L (SD, 79 pmol/L), respectively
(P < 0.001 for trend). At 11-year follow-up,
mean free testosterone levels for subjects in
each quartile were 248pmol/L (SD, 64pmol/L),
242 pmol/L (SD, 68 pmol/L), 229 pmol/L
(SD, 70 pmol/L) and 216 pmol/L (SD,
67 pmol/L), respectively (P < 0.001 for trend).
The proportional drop in free testosterone
levels over 11 years was approximately the
same in each quartile, ranging from 20% to
23%. On the basis of these data, it seems that
hyperinsulinaemia is associated not only with
a fall in serum total testosterone levels but
also with a fall in free testosterone levels in a
general population.
Tomi-Pekka Tuomainen, Professor of 
Epidemiology
School of Public Health and Clinical Nutrition, 
University of Kuopio, Kuopio, Finland.
tomipekka.tuomainen@uku.fi
1 Chew GT, Gan SK, Watts GF. Revisiting the metabolic
syndrome. Med J Aust 2006; 185: 445-449. 
2 Laaksonen DE, Niskanen L, Punnonen K, et al. The
metabolic syndrome and smoking in relation to
hypogonadism in middle-aged men: a prospective
cohort study. J Clin Endocrinol Metab 2005; 90: 712-
719. http://jcem.endojournals.org/cgi/content/full/
90/2/712 (accessed May 2007).
3 Laaksonen DE, Niskanen L, Punnonen K, et al. Testo-
sterone and sex hormone-binding globulin predict
the metabolic syndrome and diabetes in middle-
aged men. Diabetes Care 2004; 27: 1036-1041.
4 Laaksonen DE, Niskanen L, Punnonen K, et al. Sex
hormones, inflammation and the metabolic syn-
drome: a population-based study. Eur J Endocrinol
2003; 149: 601-608. ❏
Gerard T Chew, Seng Khee Gan and 
Gerald F Watts
IN REPLY: We thank Tuomainen for his
interest in our review article, and for sharing
with us his data showing an inverse associa-
tion between fasting serum insulin levels and
calculated serum free testosterone levels. We
were cautious in our statement about the
relationship between hyperinsulinaemia and
free testosterone levels, as there are conflict-
ing data in the literature regarding this,1,2 and
few studies that directly measure free or
bioavailable testosterone. Moreover, there is
ongoing controversy about the calculation
of free testosterone levels using total testo-
sterone and sex hormone-binding globulin
concentrations, with the validity and assump-
tions of some of these widely used estimation
equations being called into question.3,4
We also echo the concerns of Allan et al5
about the potential pitfalls of diagnosing
hypogonadism based on testosterone levels
only. As the presence of low total (and even
calculated free) testosterone in obese men
may not necessarily reflect deficient androgen
action, the diagnosis of androgen deficiency
should only be made in the context of sup-
portive clinical features. Furthermore, in
abdominally obese men with the metabolic
syndrome, levels of sex hormone-binding
globulin and both total and calculated free
testosterone can increase following weight
loss,6 thereby obviating the inappropriate use
of testosterone supplementation in such
patients.
Gerard T Chew, Endocrinologist and 
Postgraduate Research Scholar1,2
Seng Khee Gan, Endocrinologist and Senior 
Lecturer in Medicine1,2
Gerald F Watts, Consultant Physician and 
Professor of Medicine1,2
1 School of Medicine and Pharmacology, Royal 
Perth Hospital Unit, University of Western 
Australia, Perth, WA.
2 Department of Internal Medicine and 
Department of Endocrinology and Diabetes, 
Royal Perth Hospital, Perth, WA.
gwatts@meddent.uwa.edu.au
1 Andersson B, Marin P, Lissner L, et al. Testosterone
concentrations in women and men with NIDDM.
Diabetes Care 1994; 17: 405-411.
2 Simon D, Charles MA, Nahoul K, et al. Association
between plasma total testosterone and cardiovascu-
lar risk factors in healthy adult men: The Telecom
Study. J Clin Endocrinol Metab 1997; 82: 682-685.
3 Ly LP, Handelsman DJ. Empirical estimation of free
testosterone from testosterone and sex hormone-
binding globulin immunoassays. Eur J Endocrinol
2005; 152: 471-478.
4 Liu PY, Death AK, Handelsman DJ. Androgens and
cardiovascular disease. Endocr Rev 2003; 24: 313-
340.
5 Allan CA, Strauss BJ, Burger HG, et al. The associa-
tion between obesity and the diagnosis of androgen
deficiency in symptomatic ageing men. Med J Aust
2006; 185: 424-427. 
6 Niskanen L, Laaksonen DE, Punnonen K, et al.
Changes in sex hormone-binding globulin and testo-
sterone during weight loss and weight maintenance
in abdominally obese men with the metabolic syn-
drome. Diabetes Obes Metab 2004; 6: 208-215. ❏
Genotype and adverse drug 
reactions to warfarin
Keith A Byron and Anthony E Dear
TO THE EDITOR: The recent article by
Miller and colleagues regarding adverse drug
events (ADEs) in general practice highlights
the high frequency and considerable morbid-
ity associated with ADEs in the general com-
munity.1 The authors identified recognised
side effects, drug sensitivity, and allergy as
responsible for most ADEs.
The contribution of the patient’s genotype
to drug response, via altered metabolism or
responsiveness to pharmaceuticals, is increas-
ingly recognised as potentially responsible for
a significant proportion of ADEs.
The science of determination of the genetic
contribution to an individual’s response to
drug action is referred to as pharmacogenom-
ics,2 and represents a potentially beneficial
diagnostic tool to aid in the prevention of
ADEs.
Treatment with warfarin, one of the most
frequently prescribed drugs in Australia, has
been estimated to account for up to15.1% of
all severe ADEs, manifest as minor and major
bleeding.3
We have recently determined the presence,
frequency and laboratory sequelae of genetic
variants (single nucleotide polymorphisms)
in two genes responsible for the metabolism
(cytochrome P450 2C9 [CYP2C9]) andMJA • Volume 187 Number 1 • 2 July 2007 61
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plex, subunit 1 [VKORC1]) of warfarin4 in an
Australian population. In our study of 120
patients in an anticoagulation clinic, the fre-
quencies of allelic variants of the CYP2C9 and
VKORC1 genes responsible for altered warfa-
rin activity were 31%5 and 59% (unpub-
lished data), respectively, in keeping with
previously published studies.4 Detection of
these variants was associated with increased
induction international normalised ratio
(INR) readings compared with controls, and
reduced overall warfarin requirements.6
These findings support previous studies,7
and suggest that genotype determination may
be of benefit in identification of patients with
increased sensitivity to empiric induction
phase warfarin dosing schedules. This may
allow for a reduction of induction doses of
warfarin, decreasing the risk of excessive INR
and bleeding sequelae, commonly observed
with induction of warfarin treatment. Fur-
thermore these benefits may aid in reduced
time to stabilisation.
Additional cost–benefit analysis8,9 will ena-
ble determination of the economic viability of
genotype determination as an adjunct to
management of warfarin dosing.
The high population frequency of genetic
variants associated with warfarin response
emphasises the significant contribution
genetic factors can play in patient reaction to
drugs and highlights their involvement as
potential causes of ADEs.
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Lack of consistency in safe-
sleeping messages to parents
Roger W Byard, Glenda Cains, Helen 
Noblet and Maxine Weber
TO THE EDITOR: V-shaped pillows (“tri-
pillows”) may cause suffocation of an infant
left to sleep between the two arms of the
pillow when he or she slips into the crevice
between the arms, or beneath the pillow. The
deaths of two infants who died in this man-
ner were reported in South Australia in 1997,
and a third death was the subject of a coronial
inquiry.1,2 In 1998, the SA State Coroner
recommended that “a public warning be
issued against the use of tri- or U-shaped
pillows by infants under two years of age for
sleeping”.2 This message has also been issued
in subsequent safe-sleeping campaigns, with
a statement in the SIDS and Kids national
“Safe sleeping” brochure3 that “tri-pillows are
too soft and can cover baby’s face”, and a
statement on the SA Child and Youth Health
website that “. . . babies should not be left in
these pillows while they are sleeping”.4
Despite these clear messages, deaths continue
to occur in SA,5 and V-shaped pillows are still
being sold in the foyer of a local obstetric
hospital. Although the pillows are being pro-
moted to assist breastfeeding, infants who
have been left to sleep on them will be
exposed to the risk of suffocation.
Deaths of infants in shared sleeping situa-
tions may also occur due to suffocation from
“overlaying”. However, parents are still being
advised by health advice telephone enquiry
services to sleep in the same bed with their
children. This was the unequivocal message
given to one of the authors (G C) when she
recently telephoned for advice following the
birth of her first child. No mention was made
of the potential danger of suffocation if par-
ents are physically large, intoxicated, sedated,
or simply exhausted, or if the infant is placed
between the parents under bedcovers.
It appears, despite clear evidence that cer-
tain sleeping situations are potentially dan-
gerous for infants, as well as the widespread
dissemination of this information in safe-
sleeping literature, that certain organisations
or individuals continue to give a contrary
message. What hope do parents have of
understanding these issues and making
informed decisions to optimise the safety of
their infant’s sleeping environment if they are
exposed to such conflicting messages and
advice? Perhaps another question to ask is,
“What responsibility do organisations and
employees bear if an infant dies as a result of
parents following such advice or purchasing
equipment such as a V-shaped pillow?”
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LETTERSMycobacterium ulcerans 
infection: an eponymous ulcer
Derek H Meyers
TO THE EDITOR: Bairnsdale ulcer is
known by the eponyms Buruli in Uganda,
Kakerifu in Zaire, Kumusi in New Guinea,
and was formerly referred to as Searls’ ulcer
in Australia. In the original 1948 article
describing the causative organism,1 MacCal-
lum and colleagues acknowledged assist-
ance from Drs Alsop, Clay and Searls, in that
(alphabetical) order. In sending material to
Melbourne for examination, these doctors of
the Bairnsdale Clinic described the ulcers,
and also commented on the similarity of
their appearance in the first three patients.
JR Searls, after whom the ulcer was origi-
nally named, was regarded as an excellent
general practitioner. He died in 1971.
Derek H Meyers, Retired Physician
Brisbane, QLD.
d&rmeyers@acenet.net.au
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Paul D R Johnson and John A Hayman
“What’s in a name? That which we call a rose 
By any other name would smell as sweet.”
 — William Shakespeare,
Romeo and Juliet; II, ii, 1-2; circa 1595
COMMENT: In 1948, MacCallum and col-
leagues published an article reporting a
new mycobacterial infection in man,1 and
later named the causative organism
Mycobacterium ulcerans. In their article,
they described six patients, five of whom
came from the Bairnsdale district in Gipps-
land, Victoria. Three Bairnsdale general
practitioners, Drs Alsop, Clay and Searls,
had initially recognised a novel disease in
their region and submitted pathological
specimens to Melbourne University for
diagnosis.2
Subsequently, the same disease was
described in many different areas, mostly in
Africa (“Buruli ulcer”). Each new outbreak
tended to give rise to a new name; of all
these, perhaps the most colourful is “Sik
belong Sepik”, describing the infection as it
occurs along the Sepik River in Papua New
Guinea. In Victoria, where most Australian
cases of M. ulcerans infection occur,3 we
have continued to use the term “Bairnsdale
ulcer” even though the main endemic areas
are now the Bellarine and Mornington
Peninsulas near Melbourne.3
Medical eponyms have a place for dis-
eases that are poorly understood or have
unknown causes, but it could be argued that
the terms “Bairnsdale ulcer” and “Buruli
ulcer” now belong in the annals of medical
history.
However, there are other considerations.
In 1998, the World Health Organization
launched the Global Buruli Ulcer Initia-
tive.4 This successful advocacy raised the
profile of this neglected disease and facili-
tated major improvements in diagnosis and
treatment.
For better or worse, “Buruli ulcer” has
become the internationally recognised term
for M. ulcerans infection, and we propose
that we should now also adopt this name in
Australia. While this should come as a relief
to the good citizens of Bairnsdale and the
Bellarine peninsula, what about those of
Buruli in Uganda? Fortunately, their county
has been renamed and is now known as the
Nakasongola District.5
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Mycobacterium ulcerans 
infection in Brazil
Vitorino M dos Santos, 
Flávio L Noronha, Érica C Vicentina and 
Camila C Lima
TO THE EDITOR: Recent articles in the
Journal referred to clinical characteristics of
lesions caused by Mycobacterium ulcerans in
Australia, and to recommendations and
challenges in their management.1-3
Brazil may also be an endemic area of this
devastating neglected but treatable disease.
In developing countries, cases of Bairnsdale
or Buruli ulcer (BU) can be misdiagnosed or
underreported because neither the general
public nor health care workers have suffi-
cient knowledge about the disease, and
because affected people usually have little
contact with the health care system, or do
not seek prompt treatment.4 Expensive tests
like the polymerase chain reaction are not
available to confirm all suspicious cases, and
smears can give a low diagnostic yield; there
are often minimal histopathological changes
and absence of bacilli, particularly in
patients with long-standing lesions previ-
ously treated with effective antimicrobial
drugs.4
We report the case of a 65-year-old Brazil-
ian woman with a 2-year history of BU in
her extremities coexistent with osteomyelitis
in the fourth cervical vertebra (Figure 1),
and evidence of inadequate nutrition.
Although she had received BCG vaccine as
an infant, mycobacteria osteomyelitis devel-
oped in the site of an arthrodesis performed
in 1998 to treat an accidental fracture.4,5
This patient had lived in a poor riverside
rural area with a humid, hot climate. As in
descriptions of Australian cases, our patient
was much older than the age (5–15 years) at
which most cases of M. ulcerans infection are
reported in tropical and subtropical
1: X-ray image of osteomyelitis (arrows) 
affecting the body of the fourth cervical 
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terised through positive cultures for M.
ulcerans in samples from skin and bone
lesions, the main differential diagnosis was
ulcers resulting from fungal infection and
leishmaniasis,4 conditions that are fre-
quently seen in the region where she lived.
The earlier skin lesions had appeared in May
2004 as papules and nodules, and evolved
as painless, chronic, indolent ulcers with
undermined edges.2,4 Despite treatment in
another hospital that included surgery as
well as medical therapy with rifamycin,
aminoglycoside and quinolone antibiotics,
the disease recurred. On admission to our
hospital in August 2006, she had an exten-
sive ulcer on her left arm in addition to scars
on the right inner thigh (Figure 2).
After nearly 2 months of hospitalisation,
the patient was discharged to continue anti-
microbial therapy with outpatient follow-
up. Despite this, the lesions are healing very
slowly.
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